Amitriptyline; Antidepressant; Major depression; Nefazodone
Abstract :
[en] Nefazodone, a phenylpiperazine antidepressant, exhibits novel dual activity on serotonin (5-HT) neurons; it binds to 5-HT2 receptors and inhibits 5-HT reuptake. Flexible doses of nefazodone (100-400 mg/day) and amitriptyline (50-200 mg/day) were compared in 106 major depressive inpatients in a 6-week double-blind study. Results showed significant superiority of amitriptyline over nefazodone on all rating instruments: Montgomery and Asberg depression rating scale (P < 0.0001), Hamilton depression scale (P < 0.0006), Clinical Global Impressions (P < 0.0001) and Patient Global Assessment (P < 0.01). A total of 65% of patients under amitriptyline and 56% of patients under nefazodone reported adverse events during the study, with significantly more dry mouth in the amitriptyline group (39% versus 11%, P = 0.001). Modal daily doses within the last treatment week reached 242 mg with nefazodone and 124 mg with amitriptyline. The lower efficacy of nefazodone, which contradicts comparative trials with imipramine in US patients, is discussed with regard to the dose of nefazodone, probably below the optimal therapeutic range for melancholic patients, and to the clinical differences between the patient samples.
Disciplines :
Pharmacy, pharmacology & toxicology
Author, co-author :
Ansseau, Marc ; Université de Liège - ULiège > Département des sciences cliniques > Psychiatrie et psychologie médicale
Orban, Pierre ; Université de Liège - ULiège > Centre de recherches du cyclotron
Lecoq, Arlette ; Université de Liège - ULiège > Département de personne et société > Département de personne et société
De Nayer, André Roch; Clinique Sainte-Thèrèse, Montignies-sur-Sambre
Andrade R., Nicoll R.F. (1987) Pharmacologically distinct actions of serotonin on single pyramidal neurones of the rat hippocampus recorded in vitro. J Physiol 394:99-124.
Ansseau M. (1992) The Atlantic gap: clinical trials in Europe and the United States. Biol Psychiatry 31:109-111.
Ansseau M., von Frenckell R., Mertens C., De Wilde J., Botte L., Devoitille J.M., Evrard J.L., De Nayer A., Darimont P., Dejaiffe G., Mirel J., Meurice E., Parent M., Couzinier J.P., Demarez J.P., Serre C. (1989) Controlled comparison of two doses of milnacipran (F 2207) and amitriptyline in major depressive impatients. Psychopharmacology 98:163-168.
Ansseau M., von Frenckell R., Papart P., Mertens C., De Wilde J., Botte L., Devoitille J.M., Evrard J.L., De Nayer A., Koch-Bourdouxhe S., Darimont P., Lecoq A., Mirel J., Couzinier J.P., Demarez J.P., Serre C. (1989) Controlled comparison of milnacipram (F2207) 200 mg and amitriptyline in endogenous depressive inpatients. Hum Psychopharmacol 4:221-227.
Ansseau M., Devoitille J.M., Papart P., Vanbrabant E., Mantanus H., Tiit-Berthier M. (1991) Comparison of adinazolam, amitriptyline, and diazepam in endogenous depressive inpatients exhibiting DST nonsuppression or abnormal contingent negative variation. J Clin Psychopharmacol 11:160-165.
Ansseau M., von Frenckell R., Gérard M.A., Mertens C., De Wilde J., Botte L., Devoitille J.M., Evrard J.L., De Nayer A., Darimont P., Mirel J., Troisfontaines B., Toussaint C., Couzinier J.P., Demarez J.P., Serre C. (1991) Interest of a loading dose of milnacipran in endogenous depressive inpatients: comparison with the standard regimen and with fluvoxamine. Eur Neuropsychopharmacol 1:113-121.
Benfield P., Heel R.C., Lewis S.P. (1986) Fluoxetine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 32:481-508.
Bobon D. (1987) Us et abus des échelles d'évaluation en psychopathologie. Psychiat-Psychobiol 2:379-385.
D'Amico M.F., Roberts D.L., Robinson D.S., Schwiderski U.E., Copp J. (1990) Placebo-controlled dose-ranging trial designs in phase II development of nefazodone. Psychopharmacol Bull 26(1):147-150.
(1986) Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psychopharmacology , Danish University Antidepressant Group; 90:131-138.
(1990) Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord , Danish University Antidepressant Group; 18:289-299.
(1993) Molclobemide: a reversible MAO-A-inhibitor showing weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord , Danish University Antidepressant Group; 28:105-116.
Dechant K.L., Clissold S. (1991) Paroxetine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in depressive illness. Drugs 41:225-253.
Eison A.S., Eison, Torrente J.R., Wright R.N., Yocca F.S. (1990) Nefazodone: preclinical pharmacology of a new antidepressant. Psychopharmacol Bull 26(3):311-315.
Feighner J.P., Pambakian R., Fowler R.C., Boyer W.F., D'Amico M.F. (1989) A comparison of nefazodone, imipramine, and placebo in patients with moderate to severe depression. Psychopharmacol Bull 25(2):219-221.
Fitton A., Faulds D., Goa K.L. (1992) Moclobemide. A review of its pharmacological properties and therapeutic use in depressive illness. Drugs 43:561-596.
.
.
Gam L.F. (1990) Inadequate dosing and pharmacokinetic variability as confounding factors in assessment of efficacy of antidepressants. Clinical Neuropharmacology 13:35-44.
ECDEU Assessment manual for psychopharmacology (revised), W., Guy, National Institute of Mental Health, Psychopharmacology Research Branch, Rockville, Md.; 1976.
Hamilton M. (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 12:56-62.
Kragh-Sorensen P., Christensen P., Gram L.F., Kristensen C.B., Pedersen O.L. (1983) Phase-4 studies in psychopharmacology. New antidepressants. Clinical pharmacology in psychiatry. Bridging the experimental therapeutic gap , L.F., Gram, et al., MacMillan, London; 114-125.
Mathieu M. New drug development: a regulatory overview, Parexel, Cambridge, Mass.; 1990.
Milne R.J., Goa K.L. (1991) Citalopram: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs 41:450-477.
Bonnes pratiques cliniques. Avis aux promoteurs et aux investigateurs pour les essais cliniques des médicaments. Texte officiel en langue française, Ministère des Affaires Sociales et de l'Emploi, Ministère chargé de la Santé et de la Famille, Direction de la Pharmacie et du Médicament, Paris, France; 1987.
Montgomery A., Asberg M. (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382-389.
